Valuation: Spero Therapeutics, Inc.

Market Cap 61.73M 55.28M 50.85M 46.08M 86.13M 5.86B 87.74M 606M 243M 3.08B 232M 227M 9.72B P/E 2026 *
-1.83x
P/E 2027 * -10.1x
Enterprise Value 61.73M 55.28M 50.85M 46.08M 86.13M 5.86B 87.74M 606M 243M 3.08B 232M 227M 9.72B EV / Sales 2026 *
239x
EV / Sales 2027 * -
Free-Float
77.34%
Yield 2026 *
-
Yield 2027 * -
1 day-4.50%
1 week-4.50%
1 month-12.40%
3 months-9.40%
6 months-57.77%
Current year-54.51%
1 week 1.04
Extreme 1.04
1.18
1 month 1.04
Extreme 1.04
1.27
Current year 1.04
Extreme 1.04
3.08
1 year 1.04
Extreme 1.04
3.08
3 years 0.51
Extreme 0.5052
3.22
5 years 0.51
Extreme 0.5052
18.35
10 years 0.51
Extreme 0.5052
23.64
Manager TitleAgeSince
Chief Executive Officer 47 10/01/2025
Chief Tech/Sci/R&D Officer 69 27/07/2026
Chief Operating Officer 58 01/02/2023
Director TitleAgeSince
Chairman 69 01/01/2014
Director/Board Member 62 01/09/2015
Chairman 56 10/01/2025
Date Insider Type Main position Quantity % Market Cap. Importance
3/8/26 Free

Chief Technology Officer

486,986 0.8411%
4/5/26 Sell

Chief Executive Officer

-25,240 0.0436%
6/2/26 Sell

Chief Executive Officer

87,917 0.1560%
Change 5-day change 1-year change 3-year change Capi.($)
-4.50%-4.50%-56.38%-1.85% 61.73M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -0.15%+6.34%+37.18%+175.30% 39.44B
Weighted average by Cap. +0.18%+5.44%+47.98%+176.64%

Financials

2026 *2027 *
Net sales 258K 231K 213K 193K 360K 24.5M 367K 2.53M 1.02M 12.89M 968K 948K 40.64M -
Net income -33.46M -29.96M -27.56M -24.97M -46.68M -3.18B -47.55M -329M -132M -1.67B -126M -123M -5.27B -51.5M -46.12M -42.43M -38.44M -71.86M -4.89B -73.2M -506M -203M -2.57B -193M -189M -8.11B
Net Debt - -
Projected Income Statement - Annual - Spero Therapeutics, Inc.
Logo Spero Therapeutics, Inc.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Employees
25
Date Price Change Volume
30/10/26 USD 1.060 -4.50% 309,868
29/10/26 USD 1.110 -5.13% 209,727
28/10/26 USD 1.170 +2.63% 338,851
27/10/26 USD 1.140 +6.54% 507,845
26/10/26 USD 1.070 -3.60% 513,867
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Spero Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.060USD
Average target price
5.333USD
Spread / Average Target
+403.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Spero Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SPRO Stock